While the coronavirus vaccine produced by Johnson & Johnson (NYSE: JNJ) has faced a series of hurdles in its development, the latest clinical news is nothing but positive.
The firm has announced data showing its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant.
Now dominant in the UK and elsewhere, the variant is known to be significantly more transmissible, and is believed to be potentially more dangerous than other variants.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze